Search results for "orti"

showing 10 items of 7644 documents

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

2019

Background Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still lacking. Therefore, we provide here the first meta-analysis on this topic. Methods We searched SCOPUS and PubMed through July 2018 to identify all studies that investigated the prognostic role of ALT in sarcomas. We considered the risk of death (risk ratio, RR) calculated as the number of death vs. total participants during follow-up in ALT+ versus ALT- pati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisMesenchymalSurvivalALTlcsh:RC254-282digestive systemRisk Assessmentnot known03 medical and health sciences0302 clinical medicineSurgical oncologyInternal medicineGeneticsmedicineHumansClinical significanceALT; ATR; ATRX; Mesenchymal; Prognosis; Sarcoma; SurvivalProportional Hazards Modelsbusiness.industryHazard ratioSoft tissueTelomere HomeostasisSarcomaMiddle AgedTelomeremedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisSurvival Analysisdigestive system diseases3. Good health030104 developmental biologyATRATRXOncology030220 oncology & carcinogenesisRelative riskMeta-analysisSarcomabusinessResearch ArticleBMC Cancer
researchProduct

Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation

2020

Abstract The MTOR gene encodes the mechanistic target of rapamycin (mTOR), which is a core component of the PI3K-AKT-mTOR signaling pathway. Postzygotic MTOR variants result in various mosaic phenotypes, referred to in OMIM as Smith-Kinsgmore syndrome or focal cortical dysplasia. We report here the case of a patient, with an MTOR mosaic gain-of-function variant (p.Glu2419Lys) in the DNA of 41% skin cells, who received compassionate off-label treatment with everolimus for refractory epilepsy. This 12-year-old-girl presented with psychomotor regression, intractable seizures, hypopigmentation along Blaschko's lines (hypomelanosis of Ito), asymmetric regional body overgrowth, and ocular anomali…

0301 basic medicineOncologyCompassionate Use Trialsmedicine.medical_specialty[SDV]Life Sciences [q-bio]030105 genetics & heredityMuscle hypertrophyCraniofacial Abnormalities03 medical and health sciencesInternal medicineGeneticsmedicineHumansEverolimusChildMechanistic target of rapamycinProtein Kinase InhibitorsGenetics (clinical)PI3K/AKT/mTOR pathwayHypopigmentationEverolimusbiologybusiness.industryMosaicismTOR Serine-Threonine KinasesNeuropsychologyGeneral MedicineCortical dysplasiamedicine.disease3. Good healthClinical trialMalformations of Cortical Development[SDV] Life Sciences [q-bio]030104 developmental biologyPhenotypeGain of Function Mutationbiology.proteinFemaleEpilepsies Partialmedicine.symptombusinessmedicine.drug
researchProduct

Red Blood Cell Distribution Width, Vascular Aging Biomarkers, and Endothelial Progenitor Cells for Predicting Vascular Aging and Diagnosing/Prognosin…

2018

The emerging evidence emphasizes Red blood cell distribution width (RDW) as optimal prognostic biomarker for cardiovascular diseases. However, several clinical biases impede its clinical application. Recent recommendations suggest combining RDW with other biomarkers. Accordingly, we propose evaluating the well-recognized biomarkers of vascular aging (i.e., the leukocyte telomere length and telomerase activity, and reduced levels of endothelial progenitor cells [EPCs]) with RDW, for predicting the risk for vascular aging and onset and prognosis of age-related degenerative arterial diseases, such as sporadic ascending aorta aneurysm (AAA), characterized to have an increased incidence in old p…

0301 basic medicineOncologyErythrocyte IndicesMaleTelomeraseAgingEPCs; RDW; diagnostic and prognostic AAA biomarkers; leukocyte telomere length; risk for vascular aging and sporadic AAA; telomere activityArterial diseaserisk for vascular aging and sporadic AAA0302 clinical medicineRisk FactorsLeukocytesMedicinetelomere activityEndothelial Progenitor CellsAged 80 and overMiddle AgedTelomerePrognosisAortic AneurysmC-Reactive Proteincardiovascular systemBiomarker (medicine)Vascular agingFemaleAdultmedicine.medical_specialtydiagnostic and prognostic AAA biomarkersleukocyte telomere length03 medical and health sciencesYoung AdultInternal medicinemedicine.arterySettore MED/05 - Patologia ClinicaRDWHumansVascular DiseasesProgenitor cellAgedAortabusiness.industrySettore MED/23 - Chirurgia CardiacaRed blood cell distribution widthEPCTelomere030104 developmental biologyCase-Control StudiesEPCsGeriatrics and Gerontologybusinessdiagnostic and prognostic AAA biomarker030217 neurology & neurosurgeryBiomarkersRejuvenation research
researchProduct

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

2017

Abstract Purpose: There are conflicting results concerning the prognostic value of the CpG island methylator phenotype (CIMP) in patients with nonmetastatic colon cancer. We studied this phenotype in stage III colon cancer characterized for mismatch repair (MMR), RAS, and BRAF status, and treated with adjuvant FOLFOX-based regimen. Experimental Design: Tumor samples of 1,907 patients enrolled in the PETACC-8 adjuvant phase III trial were analyzed. The method used was methylation-specific PCR, where CIMP+ status was defined by methylation of at least 3 of 5 following genes: IGF2, CACNA1G, NEUROG1, SOCS1, and RUNX3. Association between CIMP status and overall survival (OS), disease-free survi…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsAdjuvant chemotherapyColorectal cancermedicine.medical_treatmentLeucovorincolon cancer stage iiiKaplan-Meier EstimateDNA Mismatch Repair[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMethylator phenotypecolorectalCetuximabHematologyMiddle AgedColon cancer stage iiiPrognosisPhenotypeStage III Colon Cancer3. Good healthadjuvant chemotherapyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsoncologyFemaleFluorouracilmedicine.drugmedicine.medical_specialtyphenotype[SDV.CAN]Life Sciences [q-bio]/CancerGastrointestinal tumoursDisease-Free Survivalpatient prognosis03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedNeoplasm StagingChemotherapyCpG Island Methylator Phenotypebusiness.industryProportional hazards modeloxaliplatinCancerDNA Methylationmedicine.diseasedigestive system diseasesOxaliplatin030104 developmental biologyMutationCpG IslandsNeoplasm Recurrence LocalbusinessValue (mathematics)030217 neurology & neurosurgery
researchProduct

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immuno…

2018

A higher capacity to grow under hypoxic conditions can lead to a more aggressive behavior of tumor cells. Determining tumor activity under hypoxia may identify chronic lymphocytic leukemia (CLL) with aggressive clinical course and predict response to chemo-immunotherapy (CIT). A metabolic score was generated by determining pyruvate kinase and lactate dehydrogenase, key enzymes of glycolysis, ex vivo in primary CLL samples under normoxic and hypoxic conditions. This score was further correlated with clinical endpoints and response to CIT in 96 CLL patients. 45 patients were classified as metabolic high risk (HR), 51 as low risk (LR). Treatment-free survival (TFS) was significantly shorter in…

0301 basic medicineOncologyMaleChronic lymphocytic leukemiaHigh-risklcsh:Medicinechemistry.chemical_compoundRisk FactorsClinical endpointGlycolysisAged 80 and overlcsh:R5-920Hazard ratioGeneral MedicineMiddle AgedPrognosisFemaleImmunotherapymedicine.symptomIGHV@lcsh:Medicine (General)GlycolysisResearch PaperAdultmedicine.medical_specialtyLDHGeneral Biochemistry Genetics and Molecular BiologyDisease-Free Survival03 medical and health sciencesLactate dehydrogenaseInternal medicinemedicineBiomarkers TumorHumansPK M2AgedProportional Hazards Modelsbusiness.industrylcsh:RHypoxia (medical)medicine.diseaseLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyMetabolismchemistryMutationTumor HypoxiabusinessEx vivoCLLEBioMedicine
researchProduct

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

2018

Abstract Background Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited. Patients and methods Here, we applied the computational method CIBERSORT to generate a 1028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating cell types. Forty-five genes related to peculiar prognostic cytotypes were selected and their expression …

0301 basic medicineOncologyMalePathologyHematologic MalignanciesBiopsyDatasets as TopicPredictive Value of TestDeconvolutionCohort StudiesTranscriptomeAntibodies Monoclonal Murine-Derived0302 clinical medicineprognosticatorsimmune system diseaseshemic and lymphatic diseasesTumor MicroenvironmentCluster Analysisdigital expression analysisRandomized Controlled Trials as TopicParaffin EmbeddingHematology; OncologyHematologyMiddle AgedPrognosisCorrigendaProgression-Free SurvivalAlgorithmOncology030220 oncology & carcinogenesisCell-of-originFemaleLymphoma Large B-Cell DiffuseSurvival AnalysiAlgorithmsHumanAdultmedicine.medical_specialtyStromal cellMicroenvironmentFormalin fixed paraffin embeddedPrognosiReproducibility of ResultDissection (medical)03 medical and health sciencesDigital expression analysiYoung AdultPrognosticatorPredictive Value of TestsFormaldehydeInternal medicinemedicineHumansProgression-free survivalGeneSurvival analysisAgedTumor microenvironmentCluster AnalysiProportional hazards modelbusiness.industryGene Expression ProfilingReproducibility of ResultsComputational BiologyOriginal Articlesmedicine.diseaseSurvival AnalysisGene expression profiling030104 developmental biologyDLBCLCohort StudieTranscriptomebusinessDiffuse large B-cell lymphomaDLBCL microenvironment deconvolution cell-of-origin digital expression analysis prognosticators
researchProduct

Prognostic impact and implications of extra-capsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis.

2015

The extranodal extension (ENE) of nodal metastasis (i.e. the extension of tumor cells through the nodal capsule into the perinodal adipose tissue) has recently emerged as an important prognostic factor in different types of malignancies. However, the tumor-node-metastasis (TNM) staging system for colorectal cancer does not consider it as a prognostic parameter. Therefore, we conducted a systematic review and meta-analysis to determine the prognostic role of ENE in patients with lymph node-positive colorectal cancer.Two independent authors searched PubMed and SCOPUS until 7 January 2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects wit…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerExtra-capsular extensionColon cancer; ENE; Extra-capsular extension; Extra-nodal extension; Lymph node metastasis; Rectal cancer03 medical and health sciences0302 clinical medicinecolon cancer; extracapsular extension; extranodal extension; lymph node metastasis; rectal cancerInternal medicineHumansMedicineextracapsular extensionRectal cancerProspective cohort studyLymph nodeProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelHazard ratioCancerextranodal extensionHematologyPrognosismedicine.diseaseColon cancerTreatment Outcome030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisMeta-analysisENEextranodal extension extracapsular extension lymph node metastasis colon cancer rectal cancerRegression AnalysisT-stageExtra-nodal extensionLymph NodesNeoplasm Recurrence LocalColorectal Neoplasmsbusiness
researchProduct

2019

Background Body fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gastroesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond well-established clinical parameters using robust model selection strategy such that parameters identified can be expected to generalize and to be reproducible beyond our particular data set. Then we modelled how differences in these parameters translate into survival outcomes. Methods Fat and muscle parameters were measured on baseline computed tomography scans in 761 patients with advanced gastric or gastroesophageal junction cancer from the phase III EXPA…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisProportional hazards modelbusiness.industryModel selectionCancermedicine.diseaseCorrelation03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisPhysiology (medical)SarcopeniaInternal medicineCohortmedicineOrthopedics and Sports MedicinebusinessSurvival analysisJournal of Cachexia, Sarcopenia and Muscle
researchProduct

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

2017

[EN] Background: The average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans that may play an important role in tumorigenesis. Hence, there is growing interest in studying their role as possible new biomarkers whose expression is aberrant in cancer. Therefore, in this study we identified dysregulated miRNAs by next generation sequencing (NGS) and analyzed their prognostic value. Methods: Sequencing by oligo ligation detection technology was used to identify dysregulated miRNAs in a training cohort comprising paired tumor/normal tissue samples (N = …

0301 basic medicineOncologymedicine.medical_specialtyPathologyBIOLOGIA CELULARNSCLCDNA sequencing03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerValenciaSurvival analysisbiologybusiness.industryProportional hazards modelProfilingExperimental validationbiology.organism_classificationmedicine.diseasePrognosismicroRNAsMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisNGSNon small cellPersonalized medicineprognosisprofilingbusinessResearch Paper
researchProduct

Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer.

2017

<b><i>Background:</i></b> Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays an important role as a mediator of cell migration, invasion, proliferation and survival. Conflicting results for the prognostic role of FAK in breast cancer (BC) prompted us to determine its impact. <b><i>Methods:</i></b> Patients with node-negative BC entered this retrospective study. FAK expression was determined by immunohistochemistry (n = 335). The prognostic impact of FAK was examined with Cox regression analyses and Kaplan-Meier estimation in the whole cohort as well as in different molecular subtypes. <b><i>Results:</i>&l…

0301 basic medicineOncologymedicine.medical_specialtyUnivariate analysisProportional hazards modelbusiness.industryHazard ratioRetrospective cohort studymedicine.diseaseConfidence intervalFocal adhesion03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicinemedicineImmunohistochemistrySurgeryOriginal ArticlebusinessBreast care (Basel, Switzerland)
researchProduct